Insights

Innovative Cell Platform Inceptor Bio's proprietary OUTLAST™ platform reprograms T cells to enhance their tumor microenvironment resilience, offering a differentiated approach in next-generation cell therapies that could appeal to stakeholders seeking cutting-edge cancer treatments.

Expanding Pipeline The company's development of CAR-T, CAR-M, and NK/NKT platforms along with a strategic collaboration signifies a broad and diversified pipeline, presenting opportunities for partners interested in multiple innovative immunotherapy modalities.

Recent Funding Success With the successful closure of a $21 million Series A2 financing to support clinical development and pipeline expansion, Inceptor Bio demonstrates strong investor backing, making it an attractive partner or customer for organizations focusing on emerging biotech breakthroughs.

Growth and Infrastructure The acquisition of the Gainesville GMP facility indicates recent growth and readiness to scale manufacturing capabilities, offering potential collaborations around production services or joint development projects.

Leadership and Vision Under new CEO Matthias Schroff, the company is poised for strategic advancement, creating opportunities to align with a forward-looking biotech partner focused on innovative cancer therapies and research collaborations.

Inceptor Bio Tech Stack

Inceptor Bio uses 8 technology products and services including cdnjs, oEmbed, HubSpot, and more. Explore Inceptor Bio's tech stack below.

cdnjs

Content Delivery Network

oEmbed

Dev Tools

HubSpot

Marketing Automation

Priority Hints

Performance

SiteGround

Platform As A Service

Google Analytics

Web Analytics

RankMath SEO

Web Platform Extensions

jQuery Waypoints

Web Tools And Plugins

Inceptor Bio Email Formats	Example	Percentage
First.Last@inceptor.bio	John.Doe@inceptor.bio	49%
First@inceptor.bio	John@inceptor.bio	1%
First.Last@inceptor.bio	John.Doe@inceptor.bio	49%
First@inceptor.bio	John@inceptor.bio	1%

Inceptor Bio Email Formats

Example

Percentage

First.Last@inceptor.bio

John.Doe@inceptor.bio

49%

First@inceptor.bio

John@inceptor.bio

First.Last@inceptor.bio

John.Doe@inceptor.bio

49%

First@inceptor.bio

John@inceptor.bio

Frequently Asked Questions

Where is Inceptor Bio's headquarters located?

Inceptor Bio's main headquarters is located at 2405 Perimeter Park Drive Suite 200 Morrisville, North Carolina 27560 United States. The company has employees across 2 continents, including North AmericaAfrica.

What is Inceptor Bio's official website and social media links?

Inceptor Bio's official website is inceptor.bio and has social profiles on LinkedIn Crunchbase.

What is Inceptor Bio's SIC code NAICS code?

Inceptor Bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Inceptor Bio have currently?

As of February 2026, Inceptor Bio has approximately 23 employees across 2 continents, including North AmericaAfrica. Key team members include Chief Executive Officer: M. S.Chief Scientific Officer: M. N.Vice President Finance: J. L.. Explore Inceptor Bio's employee directory with LeadIQ.

What industry does Inceptor Bio belong to?

Inceptor Bio operates in the Biotechnology Research industry.

What technology does Inceptor Bio use?

Inceptor Bio's tech stack includes cdnjsoEmbedHubSpotPriority HintsSiteGroundGoogle AnalyticsRankMath SEOjQuery Waypoints.

What is Inceptor Bio's email format?

Inceptor Bio's email format typically follows the pattern of First.Last@inceptor.bio. Find more Inceptor Bio email formats with LeadIQ.

When was Inceptor Bio founded?

Inceptor Bio was founded in 2020.

Inceptor Bio

Q: What is Inceptor Bio's official website and social media links?

Inceptor Bio's official website is inceptor.bio. Inceptor Bio has social profiles on LinkedIn.

Q: How many employees does Inceptor Bio have currently?

Inceptor Bio has approximately 23 employees.

Q: What technology does Inceptor Bio use?

Inceptor Bio's tech stack includes AOS, X-Content-Type-Options, Elementor, Google Cloud, Adobe Fonts.

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Inceptor Bio is a clinical-stage biotech company pioneering next-generation cell therapies to cure cancer. Our proprietary OUTLAST™ platform reprograms T cells into persistent, stem-like cells capable of thriving in the hostile tumor microenvironment. 

Our thesis: Like elite athletes training at high elevation, T cells conditioned in challenging environments develop the attributes needed to thrive in the hostile tumor setting, outperforming cells grown in conventional, idealized conditions

Our lead program, IB-T101, is an autologous CD70 CAR-T therapy targeting clear cell Renal Cell Carcinoma (ccRCC).

Join us on our journey to redefine the future of cancer treatment.

Insights

Similar companies to Inceptor Bio

Roche

Bristol-Myers Squibb

Sanofi

Takeda

Johnson & Johnson

Merck

Wyeth Pharmaceuticals

AstraZeneca

Genentech

AbbVie

Biogen

Gilead Sciences

Novartis

Amgen

Inceptor Bio Tech Stack

Media & News

Inceptor Bio, LLC receives financing of $21M in Series A2.

Inceptor Bio, LLC launches website at inceptor.bio.

Inceptor Bio, LLC launches next-generation CAR-T, CAR-M, and NK/NKT platform.

Inceptor Bio, LLC is developing novel IPSC platform.

Inceptor Bio, LLC hired Matthias Schroff as Chief Executive Officer on Aug 24th '23.

Inceptor Bio, LLC invests into assets: Gainesville, FL GMP facility.

Inceptor Bio, LLC is developing CAR-T, CAR-M, and CAR-NK platforms.

Inceptor Bio's Email Address Formats